



SOCIETY OF  
ACTUARIES®

2019 **ANNUAL  
MEETING**  
& EXHIBIT

October 27-30  
Toronto, Canada

## Session 119: Life Product Update

[SOA Antitrust Compliance Guidelines](#)

[SOA Presentation Disclaimer](#)

# Session 119 | Life Product Update

Jordan Givan FSA, MAAA, CERA  
Katie van Ryn FSA, MAAA

October 29, 2019



# SOCIETY OF ACTUARIES

## Antitrust Compliance Guidelines

Active participation in the Society of Actuaries is an important aspect of membership. While the positive contributions of professional societies and associations are well-recognized and encouraged, association activities are vulnerable to close antitrust scrutiny. By their very nature, associations bring together industry competitors and other market participants.

The United States antitrust laws aim to protect consumers by preserving the free economy and prohibiting anti-competitive business practices; they promote competition. There are both state and federal antitrust laws, although state antitrust laws closely follow federal law. The Sherman Act, is the primary U.S. antitrust law pertaining to association activities. The Sherman Act prohibits every contract, combination or conspiracy that places an unreasonable restraint on trade. There are, however, some activities that are illegal under all circumstances, such as price fixing, market allocation and collusive bidding.

There is no safe harbor under the antitrust law for professional association activities. Therefore, association meeting participants should refrain from discussing any activity that could potentially be construed as having an anti-competitive effect. Discussions relating to product or service pricing, market allocations, membership restrictions, product standardization or other conditions on trade could arguably be perceived as a restraint on trade and may expose the SOA and its members to antitrust enforcement procedures.

While participating in all SOA in person meetings, webinars, teleconferences or side discussions, you should avoid discussing competitively sensitive information with competitors and follow these guidelines:

- **Do not** discuss prices for services or products or anything else that might affect prices
- **Do not** discuss what you or other entities plan to do in a particular geographic or product markets or with particular customers.
- **Do not** speak on behalf of the SOA or any of its committees unless specifically authorized to do so.
- **Do** leave a meeting where any anticompetitive pricing or market allocation discussion occurs.
- **Do** alert SOA staff and/or legal counsel to any concerning discussions
- **Do** consult with legal counsel before raising any matter or making a statement that may involve competitively sensitive information.

Adherence to these guidelines involves not only avoidance of antitrust violations, but avoidance of behavior which might be so construed. These guidelines only provide an overview of prohibited activities. SOA legal counsel reviews meeting agenda and materials as deemed appropriate and any discussion that departs from the formal agenda should be scrutinized carefully. Antitrust compliance is everyone's responsibility; however, please seek legal counsel if you have any questions or concerns.

# Presentation Disclaimer

*Presentations are intended for educational purposes only and do not replace independent professional judgment. Statements of fact and opinions expressed are those of the participants individually and, unless expressly stated to the contrary, are not the opinion or position of the Society of Actuaries, its cosponsors or its committees. The Society of Actuaries does not endorse or approve, and assumes no responsibility for, the content, accuracy or completeness of the information presented. Attendees should note that the sessions are audio-recorded and may be published in various media, including print, audio and video formats without further notice.*

# Life Product Update

2019 SOA ANNUAL MEETING  
TORONTO, OCTOBER 29, 2019

**Katie van Ryn, FSA, MAAA**



Contents

## Agenda

This portion of the presentation will focus on regulatory changes and the impact they have had on life product development

1

**Overview of regulatory changes**



2

**Life PBR deep dive**



3

**Actuarial Guideline XLIX (“AG 49”) deep dive**



4

**Key take-aways**






# Overview of regulatory changes



# 1 Life insurance industry outlook Timeline

Timeline from date of final rule to transition







1

# GAAP Long Duration Targeted Improvements (LDTI)

LDTI are profound changes to GAAP accounting for long duration contracts



## Governing body & goals

- **Governing body:** Financial Accounting Standards Board (FASB)
- **Goals:** Improve, simplify and enhance the financial reporting of long-duration contracts



## Scope & timeline

- **Scope:** Impacts both existing and new business for all long duration contracts for insurers that prepare US GAAP financial statements
- **Timeline:** Effective date of January 1, 2022 with eight quarters of comparable financials starting January 1, 2020



## Key changes

- Simplify amortization of deferred acquisition costs
- Reflect experience and updates in best estimate assumptions for traditional and limited pay liabilities
- Consistent fair value accounting for market-based guarantees
- Enhance effectiveness of required disclosures



1

## Risk-Based Capital

Refinements to the factor-based NAIC RBC framework are underway; this is in addition to changes in RBC factors at YE2018 for tax reform



### Governing body & goals

- **Governing body:** NAIC and associated committees and task forces
- **Goals:** Improve the measurement of the minimum amount of capital to support ongoing business operations for a reporting entity and across reporting entities



### Scope & timeline

- Operational risk went live at year-end 2018
- Timing for C-1 and longevity is year-end 2020 at the earliest
- Other changes are actively being considered
- NAIC continuing to do field tests for Group Capital Calculation



### Key changes

- Operational risk component = 3% of total RBC
- C-1 factors more granular
- Addition of longevity risk and possible covariance with mortality
- Capital calculated at the group level in addition to legal entity level



1

## Principles-based reserving

Life PBR will apply to life new business issued after 1/1/2020; industry implementations were generally backloaded



### Governing body & goals

- **Governing body:** National Association of Insurance Commissioners (NAIC) and associated committees and task forces
- **Goals:** Move to a principles-based framework for the calculation of life insurance reserves; right-size reserves to reduce the use of captives and reserve financing



### Scope & timeline

- Applies to all individual life policies (including reinsurance assumed) issued on or after 1/1/2020 as well as any business moved to PBR during the optional 3-year implementation period
- Requirements are prescribed in the NAIC Valuation Manual under VM-20



### Key changes

- PBR is the maximum of three reserve components; a formulaic floor and two modeled reserve components
- The NAIC Valuation Manual is a living document, with an updated version released each year; changes will be retroactive




# Life PBR deep dive



## 2 Background

This section contains select results from a survey that Oliver Wyman conducted in 2019 related to PBR implementation plans




---

Respondents were asked to describe their practices as of December 31, 2018

---




# 2 All products PBR has been analyzed on more than half of survey participants' products and implementations are heavily back-loaded




# 60%

## Life writers have analyzed the impact of PBR on more than half their products

**Impact on profitability** % of Life products



**Impact on reserves** % of Life products




- Large Decrease (-)
- Small Decrease (-)
- Small Increase (+)
- Large Increase (+)

**Exclusion testing** % of Life products

**50%** of products for which writers anticipate passing stochastic exclusion tests

**23%** of products for which writers anticipate passing deterministic exclusion tests


**% of Life products on PBR**  
Across all participants





# 2 Term


A large majority of writers have analyzed PBR on their Term products and tend to see large reserve decreases




# 90%

of Term writers have analyzed the impact of PBR on their offerings

**Impact on reserves**  
% of Term writers



**Impact on profitability**  
% of Term writers




- Large Decrease (-)
- Small Decrease (-)
- Small Increase (+)
- Large Increase (+)

**Exclusion testing**  
% of Term writers

**85%** of writers anticipate passing stochastic exclusion tests


**0%** of writers anticipate passing deterministic exclusion tests

**% of Term products on PBR**  
Across all participants%






# 2 Universal life with secondary guarantee (ULSG) PBR readiness for ULSG is the second highest and most participants are seeing small changes in profitability under PBR




# 74%

of ULSG writers have analyzed the impact of PBR on their offerings

**Impact on reserves**  
% of ULSG writers



**Impact on profitability**  
% of ULSG writers




- Large Decrease (-)
- Small Decrease (-)
- Small Increase (+)
- Large Increase (+)

**Exclusion testing**  
% of ULSG writers

**21%** of writers anticipate passing stochastic exclusion tests

**0%** of writers anticipate passing deterministic exclusion tests


**% of ULSG products on PBR**  
Across all participants








# 2 Whole Life (WL) Adoption is delayed to Q4 2019 and beyond for a majority of WL writers and most expect to be exempt from modeled reserve requirements




# 56%

of WL writers have analyzed the impact of PBR on their offerings

**Impact on reserves**  
% of WL writers



**Impact on profitability**  
% of WL writers




- Large Decrease (-)
- Small Decrease (-)
- No impact
- Small Increase (+)
- Large Increase (+)

**Exclusion testing**  
% of WL writers

**87%** of writers anticipate passing stochastic exclusion tests


**77%** of writers anticipate passing deterministic exclusion tests

**% of WL products on PBR**  
Across all participants






## 2 Indexed universal life with secondary guarantee (IUL SG) A majority of writers have analyzed PBR on their IUL SG products and tend to see small impacts on reserves and profitability




# 57%

of IUL SG writers have analyzed the impact of PBR on their offerings

**Impact on reserves**  
% of IUL SG writers



**Impact on profitability**  
% of IUL SG writers




- Large Decrease (-)
- Small Decrease (-)
- Small Increase (+)
- Large Increase (+)

**Exclusion testing**  
% of IUL SG writers

**12%** of writers anticipate passing stochastic exclusion tests


**0%** of writers anticipate passing deterministic exclusion tests

**Number of IUL SG products on PBR**  
Across all participants






## 2 Variable universal life with secondary guarantee (VUL SG) Less than half of writers have analyzed PBR on their VUL SG products and tend to see small decreases in profitability




# 45%

of VUL SG writers have analyzed the impact of PBR on their offerings

**Impact on reserves**  
% of VUL SG writers



**Impact on profitability**  
% of VUL SG writers




- Large Decrease (-)
- Small Decrease (-)
- Small Increase (+)
- Large Increase (+)

**Exclusion testing**  
% of VUL SG writers

**36%** of writers anticipate passing stochastic exclusion tests

**9%** of writers anticipate passing deterministic exclusion tests

**Number of VUL SG products on PBR**  
Across all participants





# Actuarial Guideline XLIX ("AG 49") deep dive



# 3 Key provisions

## AG 49 aims to provide guidance in determining a maximum illustrated rate and to limit policy loan leverage for EIUL illustrations

1

### Benchmark Index Account

1-year point-to-point S&P 500 index account. Annual cap, 100% participation rate, 0% annual floor.

2

### Back casting

Average of 25-year geometric average rates of return beginning 66 years before the current calendar year

3

### Disciplined current scale

Earned interest rate is capped by 145% of the general account net investment earnings rate (excluding hedges)

4

### Policy Loans

Difference between assumed illustrated credited rate on borrowed amounts and illustrated loan charged rate is limited to 100bps

5


### Disclosures

“Alternative Scale” which assumes 100% allocation to fixed account  
Max/min values from the back casting calculation



# 3 Regulatory Timeline

AG 49 has been in place since 9/1/2015 for early adopters and has been mandatory since 3/1/2017



As sales of IUL products continue to increase, renewed focus is required on AG49



### 3 Product design

New product designs that have emerged since AG 49 have sparked concerns over the effectiveness of the regulation

“ *There is an IUL illustration activity that is raising red flags... In particular, IUL policies that use indexed return multipliers did not exist when AG 49 was developed.* ”

Fred Andersen, Chair of the NAIC's IUL Illustration (A) Subgroup

---

The IUL illustrations subgroup was reformed and is holding meetings to discuss future changes to AG 49

---



# 3 Current discussions

## A “Menu of Options” was developed from the IUL illustration subgroup discussions

**MENU OF OPTIONS - IUL ILLUSTRATIONS - MAY 24, 2019**

ID	(D)isclosure* or (B)eyond Disclosure	Category	Possible Details	Requiring change beyond AG 49?	Undo past AG 49 decision?
1	D	Summary Page of key metrics	Compare accumulated value by duration & lapse duration under standardized scenarios		
2	D	Signatures required on key pages	On pages disclosing charges, loan impact, potential downside		
3	D	Disclose charges & credits	Including transparency regarding growth from the multipliers, bonuses, high par rate		
4	D	Demonstrate volatility	Add lower illustration, add multiple scenarios, disclose sequence of returns		
5	D	Project up and down index performance	Add two one-year projections: one increasing 20% for the year, the other decreasing 20%		
6	D	Clarify alternate scale	Same allocation as illustrated scale or 100% allocation to fixed option?		
7	D	Follow spirit of AG 49	Reasonable net returns and limitations on loan leverage		
8	D	Illustrate reasonable growth and minimal (guaranteed) growth	Zero growth should be one illustration if zero is the guarantee		
9	D	Update illustrations every x years	Possibly every 5 years		
10	D	Provide narrative statement on downside	Possibility of worse performance than illustrated, volatility, insufficient premium		
11	D	Disclose premium required to achieve goals	Under different credited interest assumptions	?	
12	D	Show cost and value of insurance instead of the risk-return tradeoff in investments	Compare the IUL and S&P 500 accumulations to the IUL guaranteed benefits		
13	B	Clarify whether charges can impact assumed earned interest underlying the DCS	Instead of hedge budget accumulated at 145%, budget + charges accumulated in some cases		
14	B	Limit the use of variable / index loans	Include all policy credits in the 1% arbitrage limit, plus other constraints		
15	B	Have consistent treatment of various IUL product types	Consistent illustrations & DCS testing for traditional, multipliers, bonuses, & high par rates		
16	B	Application of AG 49 constraints to cash value internal rate of return	Eliminate disconnect between credited rates and accumulated value		
17	B	Illustrate volatile returns, not constant growth	Replace illustrated scale with multiple illustrations showing upside and downside	x	
18	B	Use Monte Carlo simulations instead of single credited rate	Produce likelihood of policy surviving to certain age	x	
19	B	Converge indexed annuity and indexed life insurance illustration requirements	Have scales representing the worst, best, and average historical periods	x	
20	B	Make structural changes to life illustrations	Would be an A Committee decision & issue	x	
21	B	Review Life Illustrations Model Regulation #582	Would be an A Committee decision & issue	x	
22	B	Cap illustrated rates at 110% of fixed account rate	Eliminate the Benchmark Index Account and options return assumption within AG 49		x
23	B	Place hard ceiling on the credited rate & accumulated values	e.g., no credited rates of over 6.75% or accumulated value increases above x%		x

\* Disclosure means will not impact numbers in the illustrated scale or the disciplined current scale provided at sale

Source: <https://content.naic.org/sites/default/files/inline-files/IUL%20Illustration%20Menu%20of%20Options%20-%2020052419.pdf>





### 3 | Current discussions The “Menu of Options” was simplified to two questions for immediate attention

1 **“Should a product with the multiplier feature illustrate a higher scale than a product without multiplier features?”**

2 **“To what extent should the 145% disciplined current scale factor apply to charges supporting bonuses and multipliers?”**

---

The December NAIC meeting is the earliest that changes to AG 49 could go into effect

---



# Key takeaways



# 4 | Takeaways

- 1 The impact of potential regulatory changes should be considered throughout the product development process**
- 2 2017 CSO and PBR implementations will create significant changes to individual life product offerings over the next few months**
- 3 There is a continued precedent of regulatory intervention in areas for which significant discretion exists**



# Life Product Update


2019 SOA Annual Meeting

# Current market snapshot

# Perspective


## The size of our life market (US)

Consumer spend: 1% of GDP  
Risk covered: \$20 trillion  
Lives: 57% of pop.  
Protection Gap: **\$27 trillion**



# Declining Policy Sales

*After stabilizing for a few years after the financial crisis, the number of newly issued individual life policies fell below 10 million in 2013, the lowest level since the industry began tracking this statistic in 1940*





Sources: ACLI, LIMRA, Swiss Re ER&C



# What's Being Sold

## Product type breakdowns




Source: *US Individual Life Insurance Yearbook* by LL Global/LIMRA 2018


# How it's Sold

## Distribution channel breakdown

2018 by premium volume, sum assured, and policies



2018 average policy sizes



Source: *US Individual Life Insurance Yearbook* by LL Global/LIMRA 2018

# Life + ...

## Riders and combination products

- Waiver of premium
- Term conversion
- Acceleration for terminal and chronic illness
- Long-term care

# Accelerated underwriting

# Current state

**Adoption by product**  
~80% term  
~40% UL  
~30% WL

**Common cutoffs**  
max age: 60  
max face: \$1m

**Avg. straight through**  
~40% eligible  
~15% AUW

# What's ahead



---

## Expansion

By increasing age and/or face amount limits, STP can be increased but tradeoff between UW savings and mortality cost becomes more tenuous.



---

## EHRs

Potential to source APS-type information more effectively. However, current hit rates are relatively low and its application is uncertain.



---

## Monitoring

As mortality experience will take time to emerge, random holdouts and post-issue audits are key to study UW decisions.



---

## PBR

Setting an appropriate mortality assumption. Considerations of using prior company experience and setting an appropriate load.



---

## NY Circular

AUWG developing best practice proposal. Vendors and carriers needing to prove lack of discrimination.

# Potential market disruptors

## New Entrants Overview

Many relatively small new entrants with several incumbents launching own DTCs

Target audience: millennials, young parents


Products: 10, 15, 20, 30 year term

Offering more than convenience

### Challenges

- direct channel declining 1% last 5 years
- our industry vs the disrupted
- social responsibility vs alternatives

Life start-ups (since 2014) total funded USD mn



Source: *Millennials & Modern Insurance* by Coverager, 2018





Any questions?



# Legal notice

©2019 Swiss Re. All rights reserved. You may use this presentation for private or internal purposes but note that any copyright or other proprietary notices must not be removed. You are not permitted to create any modifications or derivative works of this presentation, or to use it for commercial or other public purposes, without the prior written permission of Swiss Re.

The information and opinions contained in the presentation are provided as at the date of the presentation and may change. Although the information used was taken from reliable sources, Swiss Re does not accept any responsibility for its accuracy or comprehensiveness or its updating. All liability for the accuracy and completeness of the information or for any damage or loss resulting from its use is expressly excluded.